| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
2'-MeCCPA targets the A1 adenosine receptor (A1AR), a G protein-coupled receptor that is activated by the endogenous nucleoside adenosine. The A1AR is widely distributed in the central nervous system and peripheral tissues, where it mediates various physiological effects including inhibition of neurotransmitter release, bradycardia, and analgesia. 2'-MeCCPA is a potent and highly selective agonist of the A1AR. Its high selectivity for A1 over A2A, A2B, and A3 receptors makes it a valuable tool for studying A1AR-mediated signaling pathways. Upon binding to the A1AR, the compound activates Gi/o proteins, leading to inhibition of adenylyl cyclase and a decrease in cAMP levels.
|
|---|---|
| ln Vitro |
In vitro, 2'-MeCCPA demonstrates potent and selective agonism at the A1 adenosine receptor. In radioligand binding assays, it exhibits Kᵢ values of 1.8 nM for A1, 3900 nM for A2A, and 5000 nM for A3 receptors. In functional assays, it inhibits forskolin-induced activation of adenylyl cyclase in rat cortical membranes with an IC50 of 13.1 nM. The compound efficiently inhibits cAMP modulation in both direct and indirect pathway medium spiny neurons. These in vitro data confirm its high potency and selectivity for the A1AR.
|
| ln Vivo |
Upon reinfusion, the Sprague-Dawley plunger-to-risk ratio is significantly decreased by 2'-MeCCPA (1 nM-1 M) [1].
In vivo, 2'-MeCCPA has been reported to possess analgesic activity. As an A1AR agonist, it is expected to produce central nervous system effects including sedation, hypothermia, and neuroprotection, though specific in vivo efficacy data are not detailed in the available literature. The compound is used in research to study the role of A1 adenosine receptors in various physiological and pathological processes, including pain modulation and HCV infection. It is a valuable tool for in vivo pharmacological studies targeting the A1AR. |
| Enzyme Assay |
In vitro radioligand binding assays are used to characterize 2'-MeCCPA's interaction with adenosine receptor subtypes. Membrane preparations from cells expressing human recombinant A1, A2A, A2B, and A3 receptors are incubated with a radiolabeled antagonist and varying concentrations of 2'-MeCCPA. The displacement of the radioligand is measured, and Kᵢ values are calculated. For A1AR, the Kᵢ is 1.8 nM. Functional assays measure the inhibition of forskolin-stimulated adenylyl cyclase activity, with an IC50 of 13.1 nM determined in rat cortical membranes.
|
| Cell Assay |
In vitro cell-based assays for 2'-MeCCPA are conducted in cells expressing A1 adenosine receptors. Cells are treated with the compound at various concentrations, and cAMP levels are measured using ELISA or HTRF-based assays. The compound's ability to inhibit forskolin-stimulated cAMP accumulation is assessed. In neuronal cell cultures, 2'-MeCCPA inhibits cAMP modulation in medium spiny neurons. These assays confirm the compound's functional activity as an A1AR agonist and are used to determine its potency (IC50 = 13.1 nM for adenylyl cyclase inhibition).
|
| Animal Protocol |
In vivo animal experiments with 2'-MeCCPA are typically conducted in rodent models to study pain modulation and other A1AR-mediated effects. The compound is administered via various routes (e.g., intraperitoneal, intravenous, or intrathecal) to assess its analgesic activity. Doses are determined based on in vitro potency and pharmacokinetic properties. Behavioral tests such as the tail-flick test or formalin test are used to evaluate pain responses. The compound's effects on body temperature, locomotor activity, and other physiological parameters may also be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2'-MeCCPA are not extensively documented. As a nucleoside analog, it is expected to have moderate bioavailability and may be subject to metabolism by adenosine deaminase and other enzymes. The compound has a molecular formula of C₁₆H₂₂ClN₅O₄ and a molecular weight of 383.83 (as the free base). It is typically dissolved in DMSO for in vitro studies. For in vivo administration, appropriate formulations would need to be developed. Storage recommendations are at -20°C, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for 2'-MeCCPA are limited. As a potent A1AR agonist, potential adverse effects include bradycardia, hypotension, sedation, and respiratory depression at high doses, consistent with A1AR pharmacology. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. The compound should be stored at -20°C and protected from light and moisture.
|
| References |
[1]. J Bhandal, et al. Adenosine a1 receptor activation can protect the myocardium from ischaemia reperfusion injury post reperfusion. BMJ Journals. Volume 104, Issue Suppl 3.
[2]. Muntean BS, et al. Interrogating the Spatiotemporal Landscape of Neuromodulatory GPCR Signaling by Real-Time Imaging of cAMP in Intact Neurons and Circuits. Cell Rep. 2018 Jan 2;22(1):255-268. |
| Additional Infomation |
2'-MeCCPA has CAS number 205171-12-6, molecular formula C₁₆H₂₂ClN₅O₄, and molecular weight 383.83. It is a potent and highly selective A1 adenosine receptor agonist with a Kᵢ of 1.8 nM. It exhibits high selectivity over A2A (Kᵢ = 9580 nM), A2B (Kᵢ = 37600 nM), and A3 (Kᵢ = 1150 nM) receptors. It inhibits forskolin-stimulated adenylyl cyclase with IC50 = 13.1 nM and has analgesic activity. Purity is typically ≥98%. Not approved for clinical use; for research purposes only.
|
| Molecular Formula |
C16H22N5O4CL
|
|---|---|
| Molecular Weight |
383.82998
|
| Exact Mass |
383.136
|
| CAS # |
205171-12-6
|
| PubChem CID |
10475082
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.76g/cm3
|
| Boiling Point |
643.3ºC at 760 mmHg
|
| Flash Point |
342.9ºC
|
| Vapour Pressure |
1.98E-17mmHg at 25°C
|
| Index of Refraction |
1.777
|
| LogP |
1.172
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
513
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
OCC1OC(N2C=NC3=C(N=C(N=C23)Cl)NC2CCCC2)C(C)(O)C1O
|
| InChi Key |
MMPAUXMIDJWGFO-ROMFRFKVSA-N
|
| InChi Code |
InChI=1S/C16H22ClN5O4/c1-16(25)11(24)9(6-23)26-14(16)22-7-18-10-12(19-8-4-2-3-5-8)20-15(17)21-13(10)22/h7-9,11,14,23-25H,2-6H2,1H3,(H,19,20,21)/t9-,11-,14-,16-/m1/s1
|
| Chemical Name |
(2R,3R,4R,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~651.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6053 mL | 13.0266 mL | 26.0532 mL | |
| 5 mM | 0.5211 mL | 2.6053 mL | 5.2106 mL | |
| 10 mM | 0.2605 mL | 1.3027 mL | 2.6053 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
